Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2a, Randomized, Double-blind, Placebo-controlled, Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of GSBR-1290 in Adult Overweight or Obese Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus on Metformin

NCT05762471 is registered in ClinicalTrials.gov with Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics as lead sponsor.

NCT NCT05762471
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05762471 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2a, Randomized, Double-blind, Placebo-controlled, Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of GSBR-1290 in Adult Overweight or Obese Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus on Metformin
Lead sponsor
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Phase
Phase 1/2
Overall status
Completed
Start date
January 9, 2023
Completion date
April 11, 2024
Enrollment
142 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

overweight or obesity, type2 diabetes mellitus